Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Phoenix Molecular Designs

News headline image
Phoenix Molecular Designs Dosed First Patient in Dauntless-1, a Phase 2 Clinical Trial of PMD-026 in Combination with Fulvestrant for RSK2-high Breast Cancer
From Phoenix Molecular Designs
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.